Predictors of Long-term Adverse Events After Absorb Bioresorbable Vascular Scaffold Implantation
Una pooled analysis su 1.933-pazienti dai Registri internazionali. (EuroIntervention 2018 Oct 30)
13
Novembre
Nov
2018
7 years ago
Aim of the paper is to investigate the predictors of long-term adverse clinical events after implantation of the everolimus-eluting Absorb bioresorbable vascular scaffold (BVS).
Optimal Absorb BVS implantation and the use of intravascular imaging guidance were associated to lower rates of adverse events at long-term follow-up.